| Innovation Title | Categories | Lead Inventor | |
|---|---|---|---|
|
Modified Chloropyridyl Ester Derivates as Anti-Mpro Inhibitors for Covid-19 Treatment
2021-GHOS-69204 |
Ghosh, Arun K | ||
|
Modified Alpha-ketoamide Derivates as anti-Mpro inhibitors for Covid-19 treatment
2021-GHOS-69205 |
Ghosh, Arun K | ||
|
Modified Bis-amide Derivatives as Protease inhibitors for treatment of Covid-19
2021-GHOS-69206 |
Ghosh, Arun K | ||
|
Selective Ubiquitin Specific Protease Inhibitors for Treatment of Multiple Myeloma and Other Cancers
2017-PEPE-67704 |
Pepe, Antonella | ||
|
Facile Expression and Purification of USP17 for use in Cancer Drug Discovery
2016-MESE-67455 |
Mesecar, Andrew D | ||
|
Library of Broad-Spectrum Coronavirus Therapeutics
2016-STJO-67409 |
Mesecar, Andrew D | ||
|
Dr. Andrew D. Mesecar is the Walther Professor of Cancer Structural Biology and a Professor of Biochemistry (by courtesy) at Purdue University. Dr. Mesecar received a B.S. in Chemistry from Purdue University and a Ph.D. in Biochemistry from the University of Notre Dame. His Post Doctorate was at the University of California, Berkeley. His lab gained recognition among the U.S. Department of Defense by becoming a part of the Defense Science Study Group between 2006 and 2008. Dr. Mesecar's research interests include understanding the ability of proteins and enzymes to recognize their substrates. By understanding this, they can develop therapeutics for treating cancer and infectious diseases. For additional information, visit Dr. Mesecar's Purdue Biological Sciences website: https://www.bio.purdue.edu/People/faculty_dm/directory.php?refID=770 or his Purdue Chemistry website: https://www.chem.purdue.edu/people/directory/faculty/details/91 |
|
